Previous work demonstrated that a subset of natural killer T cells in mice decreased the antitumor efficacy of live attenuated Listeria monocytogenes where the actin A and internalin B genes were genetically deleted (LMD) against murine hepatic colorectal cancer metastases. Therefore, we hypothesized that the use of specific glycolipids known to selectively stimulate natural killer T-cell subsets used alone or co-administered with LMD would increase survival. We found that early or multiple administrations of glycolipids after tumor challenge had a strong impact on survival with or without LMD. Solitary administration or treatment given later was less efficacious but still showed a strong trend toward enhancing the antitumor activity of LMD. These results underscore the potential of glycolipids in the treatment of hepatic metastases and encourage further investigations into the immunomodulation of natural killer T cells to enhance the antitumor activity of LMD.
Figure 1. α-Galactosylceramide (α-GalCer) treatment improves survival. Survival of mice after tumor challenge on day 0 (1 × 105 colon tumor 26 cells) followed by either no treatment (NT), treatment with a single dose of 1 ug of α-GalCer on day 3 (α-GalCer d3), or 3 treatments of 1 ug of α-GalCer on days 3, 6, and 9 (α-GalCer d3, 6, 9; n = 5-7 per group). P = .006 for α-GalCer on day 3 vs no treatment. P = .002 for α-GalCer on days 3, 6, and 9 vs no treatment. P value is not significant for α-GalCer on days 3, 6, and 9 vs α-GalCer on day 3.
Figure 2. α-Galactosylceramide (α-GalCer) and sulfatide enhance the impact of Listeria monocytogenes (LMD) on survival. Survival of mice after tumor challenge on day 0 (1 × 105 colon tumor 26 cells) followed by either no treatment (NT), 3 treatments of LMD on days 3, 6, and 9 (LMD), both LMD on days 3, 6, 9 and 1 ug of α-GalCer on day 3 (LMD α-GalCer), or both LMD on days 3, 6, and 9 and 25 ug of sulfatide on day 3 (LMD sulfatide; n = 6-7 per group). P = .04 for LMD vs no treatment. P = .004 for LMD α-GalCer vs no treatment. P = .005 for LMD sulfatide vs no treatment. P = .07 for LMD α-GalCer vs LMD. P = .02 for LMD sulfatide vs LMD. P value is not significant for LMD α-GalCer vs LMD sulfatide.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Surgery editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Users' Guides to the Medical Literature
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.